Cannabidiol modulates chronic neuropathic pain aversion behavior by attenuation of neuroinflammation markers and neuronal activity in the corticolimbic circuit in male Wistar rats

Autor(es)

Silva-Cardoso, Gleice K. ; Lazarini-Lopes, Willian ; Primini, Eduardo Octaviano ; Hallak, Jaime E. ; Crippa, Jose A. ; Zuardi, Antonio W. ; Garcia-Cairasco, Norberto ; Leite-Panissi, Christie R. A.

• Tipo de documento: Artigo Científico
• Fonte: Behavioural Brain Research; v. 452, p. 16-pg., 2023-08-24.

Resumo

Chronic neuropathic pain (CNP) is a vast world health problem often associated with the somatosensory domain. This conceptualization is problematic because, unlike most other sensations that are usually affectively neutral and may present emotional, affective, and cognitive impairments. Neuronal circuits that modulate pain can increase or decrease painful sensitivity based on several factors, including context and expectation. The objective of this study was to evaluate whether subchronic treatment with Cannabidiol (CBD; 0.3, 3, and 10 mg/kg intraperitoneal route -i.p., once a day for 3 days) could promote pain-conditioned reversal, in the conditioned place preference (CPP) test, in male Wistar rats submitted to chronic constriction injury (CCI) of the sciatic nerve. Then, we evaluated the expression of astrocytes and microglia in animals treated with CBD through the immunofluorescence technique. Our results demonstrated that CBD promoted the reversal of CPP at 3 and 10 mg/kg. In CCI animals, CBD was able to attenuate the increase in neuronal hyperactivity, measured by FosB protein expression, in the regions of the corticolimbic circuit: anterior cingulate cortex (ACC), complex baso-lateral amygdala (BLA), granular layer of the dentate gyrus (GrDG), and dorsal hippocampus (DH) -adjacent to subiculum (CA1). CBD also prevented the increased expression of GFAP and IBA-1 in CCI animals. We concluded that CBD effects on CNP are linked to the modulation of the aversive component of pain. These effects decrease chronic neuronal activation and inflammatory markers in regions of the corticolimbic circuit. (AU)

• Processo FAPESP: 21/13622-6 - Caracterização da ansiedade e da hipersensibilidade dolorosa como comorbidades associadas à Epilepsia: efeitos do tratamento com canabidiol e o papel dos receptores CB1, TRPV1 e 5-HT1A
• Beneficiário: Willian Lazarini Lopes
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 19/12439-3 - Canabinoides no circuito amigdaliano-parabraquial e a regulação da dor
• Beneficiário: Gleice Kelli Ribeiro da Silva Cardoso
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado
• Processo FAPESP: 22/05471-0 - Modulação da dor: efeitos do tratamento sistêmico com canabidiol e possíveis mecanismos
• Beneficiário: Christie Ramos Andrade Leite Panissi
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 18/06877-5 - Tratamento sistêmico com canabidiol em modelo de dor neuropática: avaliação dos componentes sensorial-discriminativo e emocional-motivacional da sensibilidade dolorosa
• Beneficiário: Gleice Kelli Ribeiro da Silva Cardoso
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 14/50891-1 - INCT 2014: Translacional em Medicina
• Beneficiário: Jaime Eduardo Cecilio Hallak
• Modalidade de apoio: Auxílio à Pesquisa - Temático